Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Written By: Nitin Goswami, Senior Medical Content Writer | Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Quick answer: BRAF V600E is a gene change found in roughly 1 in 10 colorectal cancers. It makes the cancer behave more aggressively, and it doesn't respond well to standard chemotherapy alone. The good news is that a simple tumor test can find it, and there's now a targeted combination for it: encorafenib (Braftovi) with cetuximab, given with chemotherapy as first treatment in the BREAKWATER trial, where median survival was 30.3 months versus 15.1 months with standard care. Braftovi can be accessed in India through a Named Patient Program with a valid prescription.
Last reviewed: September 28, 2026. Every figure in this guide is sourced in the References section at the end.
If you or someone in your family has been told about colon or rectal cancer, you've probably heard a lot of new words in a short time. Stage. Metastasis. Chemotherapy. And then, sometimes, a very specific one: BRAF.
It can sound like a small detail in a long report. It isn't. For a group of people with advanced colorectal cancer, that one line, "BRAF V600E mutation detected," changes which treatment is likely to work best. This guide explains what colorectal cancer is, how common it is, what to watch for, and what the BRAF result means for your options.
| What it is | Colon or rectal cancer whose tumor carries a BRAF V600E gene change |
|---|---|
| How common | About 8% to 10% of metastatic colorectal cancers in one large clinic series; 10.6% of metastatic cases in a population-based study |
| Why it matters | It's linked to a poorer outlook with standard treatment, and it changes which medicines make sense |
| How it's found | A tumor test (the Braftovi label also allows a plasma test). The ACS says cancers that have spread are likely to be tested |
| Targeted regimen | Encorafenib (Braftovi) with cetuximab, with or without chemotherapy |
| First-line trial result | BREAKWATER: median overall survival 30.3 vs 15.1 months; median progression-free survival 12.8 vs 7.1 months (interim analysis) |
| U.S. FDA status | Accelerated approval December 20, 2024; traditional approval February 24, 2026. Braftovi product details |
Colorectal cancer is cancer of the colon (large intestine) or the rectum, the last part of it. Many start as small growths called polyps. Most polyps cause no symptoms at all, which is why screening and early checks matter so much.
Every cancer is driven by changes in the DNA of its cells. Some of those changes are shared by many patients and can be tested for. BRAF is a gene that tells cells when to grow. In some tumors it carries a specific change called V600E, which leaves the "grow" signal permanently switched on.
That's why two people with the same stage of colon cancer can have very different treatment plans. The tumor's genetics can matter as much as where it sits.
Numbers can't tell you what will happen in your case, but they show how common colorectal cancer is and how the BRAF group differs. Every figure names its source and year.
These are 5-year relative survival rates for people diagnosed between 2014 and 2020, reported by the ACS. They describe groups, not individuals, and they're not specific to BRAF-mutated tumors.
Studies describe BRAF V600E as an aggressive subtype. A 2019 report in the New England Journal of Medicine noted that people with BRAF V600E-mutated metastatic colorectal cancer had a median overall survival of only 4 to 6 months after their first treatment stopped working. A population-based study in Clinical Cancer Research found the mutation in 10.6% of metastatic cases and reported worse outcomes than earlier estimates suggested. Those numbers are the reason doctors now treat BRAF testing as a priority, and the reason newer regimens were studied.
This guide is about the BRAF result, so here's just a quick refresher on the general picture, using the American Cancer Society's lists. For the bigger picture of what cancer is and how it develops, see our general guide.
These signs have many other causes, so don't panic, but don't wait either. If cancer has reached the liver, yellowing of the skin and eyes can follow.
Excess weight, type 2 diabetes, red and processed meat, smoking, alcohol, age, inflammatory bowel disease, and a family history all raise the risk. Inherited syndromes matter too: Lynch syndrome accounts for about 2% to 4% of colorectal cancers. Having a risk factor doesn't mean you'll get the cancer.
The ACS says that if your colorectal cancer has spread, it will likely be tested for the BRAF V600E change. It also notes that EGFR-blocking drugs such as cetuximab typically don't work in tumors with KRAS, NRAS or BRAF mutations when used on their own, which is why doctors test the tumor before treatment.
Treatment depends on the stage, where the cancer has spread, and your general health. When the cancer is localized, surgery is the main approach. What follows is about metastatic disease, where the BRAF result matters most.
Chemotherapy regimens such as FOLFOX and FOLFIRI have long been the backbone of treatment. For BRAF V600E tumors, though, they've historically had limited effect, and survival after they stopped working was short. That's the gap targeted therapy was designed to fill. And if several treatments have already been tried, options for advanced colorectal cancer after earlier therapies are covered in a separate guide.
Blocking BRAF alone doesn't work well in colorectal cancer, because the cell reactivates its growth signal through another route called EGFR. The solution researchers found was to block both at the same time, with encorafenib (a BRAF inhibitor) and cetuximab (an EGFR inhibitor).
In BEACON, 665 people with BRAF V600E-mutated metastatic colorectal cancer, all of whom had already had one or two treatments, were split into three groups. In the updated results, the encorafenib-plus-cetuximab group had a median overall survival of 9.3 months versus 5.9 months for standard chemotherapy plus cetuximab (hazard ratio 0.61). Tumors shrank in 19.5% of people on the combination versus 1.8% on standard treatment.
BREAKWATER tested the combination earlier, in people with previously untreated BRAF V600E-mutated metastatic colorectal cancer. Adding encorafenib and cetuximab to mFOLFOX6 chemotherapy gave:
That's a big difference for a tumor type that had few good options. It's still an interim survival analysis, and everyone responds differently, so treat these as group results.
Encorafenib is an oral capsule. For colorectal cancer, the FDA label dose of Braftovi is 300 mg (four 75 mg capsules) once daily, with or without food, taken together with cetuximab and, in the first-line setting, mFOLFOX6 or FOLFIRI chemotherapy. It continues until the disease progresses or side effects become unacceptable. The U.S. FDA gave accelerated approval to the first-line combination on December 20, 2024, and converted it to traditional approval on February 24, 2026. The label also covers BRAF-mutated melanoma and lung cancer, but this article focuses on colorectal cancer.
Braftovi isn't part of the regular pharmacy supply in India. If your oncologist has prescribed it, Named Patient Program can help you import it in your own name through a regulated route. We don't prescribe or recommend treatment. That decision stays between you and your doctor.
When you have your prescription and reports ready, talk to our access team about availability and timelines.
It's a specific change in the BRAF gene that keeps the cell's growth signal switched on. It's found in roughly 1 in 10 metastatic colorectal cancers and is linked to a more aggressive course.
Yes. Treatment options are better than they were a few years ago. In the BREAKWATER trial, the encorafenib and cetuximab combination with chemotherapy gave longer survival than standard care as a first treatment. Your oncologist can tell you which option fits your case.
Through a lab test on a tumor sample, or in some cases on a blood (plasma) sample. The ACS says doctors commonly test for KRAS, NRAS and BRAF changes before treatment with EGFR drugs such as cetuximab.
For colorectal cancer, it's given together with cetuximab, and in the first-line setting also with chemotherapy. Blocking BRAF alone is not enough because the cancer cell reactivates growth through EGFR.
Through a regulated Named Patient Program (see the cancer medicines we can help source), which imports the medicine in the patient's own name with a valid prescription from a qualified doctor, your diagnostic reports including the BRAF result, and Government of India ID proof.
We wouldn't recommend it. Cancer medicines from unverified sellers can be counterfeit, expired or stored wrongly, and a capsule that looks normal tells you nothing about what's inside. Named Patient Program sources Braftovi from reliable global channels against a valid prescription, with pharmacist checks, temperature-controlled shipping and batch traceability.
This page is meant to help you understand your diagnosis and prepare better questions. It isn't a substitute for medical advice. Colorectal cancer varies from person to person, so please let your oncologist decide what suits you, and don't change any treatment based on this article alone.
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.com
Contact Us:
+91 9810469557
We get back to you shortly during our working hours.